glp 1 production Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1: Actions on Beta-cell Mass
Description
References Saxenda FDA Approval History

A 2018 meta-analysis found no favorable effect of DPP-4 inhibitors on all-cause mortality, cardiovascular mortality, myocardial infarction or stroke in patients with type 2 diabetes
Acute Kidney Injury After Accelerated Dosing of Tirzepatide in a Patient with Multiple Comorbidities: A Case Report

Saxenda is manufactured by Novo Nordisk
